Cationic Lipid Nanoparticles for Nucleic Acid Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nucleic acid delivery technologies face challenges such as susceptibility to nuclease digestion in plasma and limited intracellular access, necessitating improved cationic lipids and lipid nanoparticles for optimal drug:lipid ratios, protection from degradation, and effective intracellular delivery.
Innovation Solution
Development of novel cationic lipids and lipid nanoparticles comprising these lipids, combined with neutral lipids, cholesterol, and polymer conjugated lipids, to form stable nanoparticles for nucleic acid delivery, enhancing protection and intracellular uptake.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If free nucleic acids are used for delivery, then the delivery process is simple, but the nucleic acids are susceptible to nuclease digestion in plasma and have limited intracellular access
Solution Approach 1:
The patent uses composite lipid nanoparticles comprising cationic lipids, neutral lipids, cholesterol, and polymer conjugated lipids to form a protective carrier system. This composite structure protects nucleic acids from nuclease digestion while facilitating intracellular uptake, resolving the contradiction between delivery simplicity and nucleic acid stability.
Solution Approach 2:
The lipid nanoparticle acts as an intermediary carrier between the nucleic acid and the intracellular target. The nanoparticle protects the nucleic acid during circulation through plasma and mediates its entry into cells, thereby improving both stability and intracellular access without complicating the delivery process.
2Reliability
If conventional cationic lipids are used to form lipid nanoparticles, then nucleic acid protection and intracellular delivery are improved, but the therapeutic index and tolerability are insufficient
Solution Approach 1:
The patent modifies the chemical structure and properties of cationic lipids by changing parameters such as charge density, lipid tail length, and head group composition. These parameter changes optimize the balance between nucleic acid protection, intracellular delivery efficiency, and cellular tolerability, thereby improving the therapeutic index.
Solution Approach 2:
The patent employs different lipid components with specific local functions: cationic lipids for nucleic acid binding and intracellular delivery, neutral lipids for structural stability, cholesterol for membrane integrity, and polymer conjugated lipids for extended circulation. This local quality differentiation optimizes both delivery performance and tolerability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel lipid nanoparticles provide increased therapeutic index, improved tolerability, and effective intracellular delivery of nucleic acids, including mRNA and oligonucleotides, for various therapeutic applications.
Implementation Method 1
Lipid nanoparticles formed from cationic lipids with other lipid components, such as neutral lipids, cholesterol, PEG, PEGylated lipids, and oligonucleotides have been used to block degradation of the RNAs in plasma and facilitate the cellular uptake of the oligonucleotides
Data Source
AI summary
Compounds are provided having the following structure:, (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein a, b, c, d, G1, G2, L1, L2, R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8 and X are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, nanoparticles comprising the compounds and methods for their use and preparation are also provided.